지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2011.1
- 수록면
- 616 - 623 (8page)
이용수
초록· 키워드
오류제보하기
Purpose: The present study was conducted to determine and compare the target attainment rate (TAR) between microorganism-nonspecific (C_trough) and microorganism-specific (AUC_24/MIC) targets over two weeks of teicoplanin administration according to several dose regimens for the treatment of Staphylococcus aureus in Korean patients with neutropenic fever. Materials and Methods: One thousand virtual concentrations were obtained for each dose using the population pharmacokinetic parameters of teicoplanin adopted from a published study. Simulation of 1,000 virtual MICs was performed using the MICs of 78 clinical isolates of S. aureus collected from a hospital in Korea. Thereafter, these simulated MICs were randomly allocated to 1,000 virtual patients in whom the TARs for AUC_24/MIC >125 [or 345] and C_trough >10 [or 20] mg/L were determined. The relationship of the maintenance dose with the steady-state TAR was predicted with respect to the AUC_24/MIC >125 [or 345] using logistic analysis. Results: The standard dose regimen of teicoplanin showed TARs of about 70% [or 33%] and 70% [or 20%] at steady-state in cases with AUC_24/MIC >125 [or 345] and C_trough >10 [or 20] mg/L, respectively. Conclusion: The current standard dose regimen was predicted to be insufficient to adequately treat S. aureus in Korean patients with neutropenic fever. To assure at least an 80% TAR in this population, dose adjustment of teicoplanin should be considered.
목차
등록된 정보가 없습니다.
참고문헌 (23)
참고문헌 신청
Clinical and Laboratory Standards Institute / 2006 / Performance standards for antimicrobial susceptibility testing. Sixteenth inforclinical mational supplement. Approved standard M10
Craig WA / 2003 / Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid / Infect Dis Clin North Am 17
Gimenez F / 1997 / Variations of teicoplanin concentrations in neutropenic patients / J Clin Pharm Ther 22 : 187 ~ 190
Harding I / 2000 / Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome / J Antimicrob Chemother 45 : 835
Hyatt JM / 1995 / The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents / Clin Pharmacokinet 28 : 143 ~ 160
Craig WA / 2003 / Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid / Infect Dis Clin North Am 17
Gimenez F / 1997 / Variations of teicoplanin concentrations in neutropenic patients / J Clin Pharm Ther 22 : 187 ~ 190
Harding I / 2000 / Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome / J Antimicrob Chemother 45 : 835
Hyatt JM / 1995 / The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents / Clin Pharmacokinet 28 : 143 ~ 160
이 논문의 저자 정보
최근 본 자료
댓글(0)
0